Overview

PhaseⅠFirst-in-Human Study of Hemay007 in Healthy Volunteers

Status:
Unknown status
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
This phase I study designed in 3 parts is a randomized, placebo-controlled, sequential ascending-dose study of healthy volunteers. The safety, tolerability and pharmacokinetics of ascending single and multiple dose of Hemay007 will be assessed in Part 1 and Part 3, respectively. Food effect following a single oral dose will be evaluated in Part 2.
Phase:
Phase 1
Details
Lead Sponsor:
Hemay Pharmaceutical PTY. LTD.
Collaborator:
Tianjin Hemay Pharmaceutical Co.,Ltd